Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18971854 | 1.00 | MEN1 (0.51) | MEN1KMT2APKMNPSR1TAS2R14 | |
| SCHEMBL3577297 | 1.00 | MEN1 (0.51) | MEN1KMT2APKMNPSR1TAS2R14 | |
| SCHEMBL24405180 | 0.85 | ALDH1A1 (0.48) | MEN1KMT2APKMNPSR1LMNA | |
| SCHEMBL25295156 | 0.85 | TAS2R14 (0.46) | MEN1KMT2APKMNPSR1TAS2R14 | |
| SCHEMBL13226911 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2APKMNPSR1LMNA | |
| SCHEMBL13553615 | 0.85 | ALDH1A1 (0.49) | PKMNPSR1TAS2R14LMNAHPGD | |
| SCHEMBL18211216 | 0.85 | ALDH1A1 (0.49) | KMT2APKMLMNATDP1HPGD | |
| SCHEMBL30325030 | 0.84 | TDP1 (0.47) | MEN1KMT2ATDP1MAPK1 | |
| SCHEMBL4143101 | 0.83 | ALDH1A1 (0.59) | KMT2ALMNATDP1MAPK1NPC1 | |
| SCHEMBL280126 | 0.83 | FABP7 (0.58) | KMT2APKMLMNATDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388423-B1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-10399949-B2 | NK1 receptor antagonist | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3388423-A1 | NK1 RECEPTOR ANTAGONIST | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-1973889-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | MEN1 3533/4885KMT2A 1880/4885PKM 1860/4885 |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | TACR1, TACR2, GRPR | MEN1 721/4885KMT2A 277/4885PKM 2013/4885 |
| US-10399949-B2 | NK1 receptor antagonist | TACR1, TACR2, GRPR | MEN1 721/4885KMT2A 277/4885PKM 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.